Hefty drug price increases have been an outrage-provoking subject for politicians, the public and pharmacy benefits managers all year long. But another group besides drugmakers has been benefiting from them: dealmakers.
Private companies have been taking advantage of climbing prices by buying older drugs on the cheap, hiking their stickers, and reselling them, Bloomberg reports, citing data from software company Connecture.
Take Actimmune, which a private equity outfit bought from Genentech in 2012 for $55 million, for example. Its price climbed by 434% in two years before Horizon Pharma grabbed it for $660 million.
Then there’s Novartis’ cold-sore cream Denavir, whose price leapt 372% over two transactions aided by private equity. And the list goes on and on.
Of course, drug flippers aren’t the only price-hike offenders. Plenty of drugmakers have notched sizable increases on meds that haven’t changed hands at all, and one need only look at key Mylan blockbuster EpiPen, one of Congress’ most recent price-hike scapegoats, to see it.
Instead, they’re “taking advantage of a dysfunctional market,” Stephen Schondelmeyer, a professor of pharmaceutical economics at the University of Minnesota, told Bloomberg.
One reason? There’s “very little risk” in picking up drugs, ZS Associates’ managing principal Pratap Khedkar told the news service. Other private-equity firms see a relatively quick payout on the horizon.
Of course, as pharma’s drug-pricing scandal rages on, there’s more and more possibility of winding up in an unwelcome spotlight, as Concordia Pharmaceuticals knows. The company–one of several in the specialty pharma space that’s been hit especially hard by the crackdown–recently raised prices on two meds purchased from a PE outfit that had already made its own increases.
That price lift didn’t go unnoticed by CVS Health, which kicked the drugs–Nilandron and Dutoprol, up 989% and 1,057% respectively since 2013, off its formulary.
A lot of jacked-up drugs still do fly under the radar, though, John Bennett, CEO of nonprofit insurer Capital District Physicians’ Health Plan, told Bloomberg. So, while drug flippers may not be the only group contributing to skyrocketing drug costs, “the bottom line is it all adds up,” he said.
By Carly Helfand
Source: Fierce Pharma
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
